To order this detailed 285+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Key Inclusions
§
A detailed review of the overall landscape of companies,
offering contract services for the manufacturing of antibodies, along with
information on year of establishment, company size, scale of operation
(preclinical, clinical and commercial), location of headquarters, number of
manufacturing facilities and location of these facilities, type of antibody
manufactured (monoclonal antibodies, bispecific antibodies and polyclonal
antibodies), type of expression systems used (mammalian, microbial and others),
fill / finish operations and affiliations to regulatory agencies.
§
A competitiveness analysis of key players engaged in this
domain, featuring an assessment based on their supplier strength (related to
the experience of a contract manufacturer), and service strength (which
takes into account the size of service portfolio and scale of operation).
§
A benchmark analysis, highlighting the key focus areas of
small, mid-sized and large companies, comparing their existing capabilities
within and beyond their respective (geography-based) peer groups.
§
An analysis of the various partnerships pertaining to
contract manufacturing of antibodies, which have been established since 2013,
based on several parameters, such as the year of agreement, type of
partnership, project scale and focus therapeutic area.
§
An analysis of the various expansion initiatives undertaken
by service providers, in order to augment their respective antibody
manufacturing capabilities, over the period 2017-2019 (till October),
taking into consideration parameters, such as year of expansion, type of
expansion (capacity expansion, facility expansion and new facility), type of
antibodies manufactured and location of manufacturing facility.
§
An estimate of the overall, installed capacity for
manufacturing antibodies based on data reported by industry stakeholders in the
public domain; it highlights the distribution of available antibody production
capacity on the basis of company size (small, mid-sized, large and very large
firms), scale of operation (preclinical, clinical and commercial), and key
geographical regions (North America, Europe, Asia).
§
Informed estimates of the annual commercial and clinical
demand for antibodies, based on various relevant parameters, such as target
patient population, dosing frequency and dose strength.
§
Elaborate profiles of the key industry players that offer
contract manufacturing services at all scales of operation and have more than
two manufacturing facilities. Each profile features a brief overview of the
company, information on its service portfolio, details related to its
manufacturing capabilities and facilities, and an informed future outlook.
§
A case study comparing the key characteristics of large
molecule and small molecule drugs, along with details on the various steps and
challenges involved in their respective manufacturing processes.
§
A discussion on affiliated trends, key drivers and
challenges, under a SWOT framework, which are likely to impact the industry’s
evolution, including a Harvey ball analysis, highlighting the relative effect
of each SWOT parameter on the overall pharmaceutical industry.
The report also features the likely distribution of
the current and forecasted opportunity across important market segments,
mentioned below:
§ Type
of Antibodies
§ Monoclonal
Antibodies
§ Bispecific
Antibodies
§ ADCs
§ Others
§
Company Size
§ Small
§ Mid-sized
§ Large
/ Very Large
§ Scale
of Operation
§ Preclinical
/ Clinical
§ Commercial
§ Type
of expression system used
§ Mammalian
§ Microbial
§ Key
geographical regions
§ North
America
§ Europe
§ Asia
and RoW
The report includes
detailed transcripts of discussions held with the following experts:
§ Dietmar
Katinger (Chief Executive Officer, Polymun Scientific)
§ David
C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
§ Claire
Otjes (Marketing Manager, Batavia Biosciences)
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/295/request-sample.html
Key
Questions Answered
§
Who are the leading CMOs engaged in the production of
antibody-based therapeutics?
§ What
kind of partnership models are commonly adopted by stakeholders in this
industry?
§ What
is the annual clinical and commercial demand for antibody-based products?
§ What
is the current installed capacity for manufacturing of antibodies?
§ What
are the various expansion initiatives undertaken by antibody CMOs?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be
interested in the following titles:
1.
Bispecific Antibody
Therapeutics Market
(4th Edition), 2019-2030
2.
Antibody Drug
Conjugates (ADCs)
- Linker and Conjugation Technologies Market, 2019-2030
3.
Antibody Drug
Conjugates Market
(5th Edition), 2019-2030
Contact Us
Gaurav Chaudhary
+1
(415) 800 3415
gaurav.chaudhary@rootsanalysis.com